MoFo has advised Ensem Therapeutics, Inc. (“ENSEM”), a biotechnology company focusing on high‑value and difficult-to-drug oncology targets, on its partnership with BeiGene, Ltd. (“BeiGene”), a global biotechnology company, for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Under the terms of the agreement, ENSEM will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to US$1.33 billion, in addition to tiered royalties.
The MoFo team is led by Shanghai Technology Transactions/M&A partner Chuan Sun, with the assistance of Hong Kong Technology Transactions associate Tyler Xiu; Hong Kong Tax partner Matthew Lau; Washington, D.C. FDA + Healthcare Regulatory and Compliance partner Brigid Bondoc; and San Francisco of counsel Wendy Chow.
